DK1334194T3 - Afbildning, diagnosticering og behandling af sygdom - Google Patents

Afbildning, diagnosticering og behandling af sygdom

Info

Publication number
DK1334194T3
DK1334194T3 DK01992777T DK01992777T DK1334194T3 DK 1334194 T3 DK1334194 T3 DK 1334194T3 DK 01992777 T DK01992777 T DK 01992777T DK 01992777 T DK01992777 T DK 01992777T DK 1334194 T3 DK1334194 T3 DK 1334194T3
Authority
DK
Denmark
Prior art keywords
diagnosis
imaging
treatment
disease
materials
Prior art date
Application number
DK01992777T
Other languages
Danish (da)
English (en)
Inventor
Lukasz Huminiecki
Roy Bicknell
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of DK1334194T3 publication Critical patent/DK1334194T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
DK01992777T 2000-11-06 2001-11-06 Afbildning, diagnosticering og behandling af sygdom DK1334194T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24556600P 2000-11-06 2000-11-06
US27366201P 2001-03-07 2001-03-07
PCT/GB2001/004906 WO2002036771A2 (en) 2000-11-06 2001-11-06 Imaging, diagnosis and treatment of disease

Publications (1)

Publication Number Publication Date
DK1334194T3 true DK1334194T3 (da) 2007-05-29

Family

ID=26937319

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01992777T DK1334194T3 (da) 2000-11-06 2001-11-06 Afbildning, diagnosticering og behandling af sygdom
DK06077262.1T DK1790728T3 (da) 2000-11-06 2001-11-06 Billeddannelse, diagnose og behandling af sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06077262.1T DK1790728T3 (da) 2000-11-06 2001-11-06 Billeddannelse, diagnose og behandling af sygdom

Country Status (12)

Country Link
US (5) US7498034B2 (es)
EP (2) EP1790728B1 (es)
JP (2) JP2004524821A (es)
AT (2) ATE360068T1 (es)
AU (3) AU2378402A (es)
CA (1) CA2427310C (es)
CY (2) CY1107609T1 (es)
DE (2) DE60143065D1 (es)
DK (2) DK1334194T3 (es)
ES (1) ES2296829T3 (es)
PT (2) PT1334194E (es)
WO (1) WO2002036771A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524821A (ja) * 2000-11-06 2004-08-19 キャンサー・リサーチ・テクノロジー・リミテッド 疾患のイメージング、診断、及び治療
AU2002231736A1 (en) * 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
AU2003247828B2 (en) * 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
US7185814B2 (en) * 2002-10-16 2007-03-06 Dcard, Inc. Layer structure and method of manufacture for optical memory strip (OMS)
SI1565491T1 (sl) * 2002-11-20 2010-08-31 Cancer Rec Tech Ltd Protitelesa, ki se veĹľejo na humani "magic roundabout (MR)", polipeptidi in njihove uporabe za inhibiranje angiogeneze
EP1928905B1 (de) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
CN101600451A (zh) * 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
US8399421B2 (en) * 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
WO2009046127A1 (en) * 2007-10-01 2009-04-09 Allos Therapeutics, Inc. Dt-diaphorase-active agents for treatment of pediatric tumors
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
HUE028878T2 (en) 2009-09-03 2017-01-30 Cancer Res Tech Ltd CLEC14A inhibitors
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
US20110105735A1 (en) * 2009-10-29 2011-05-05 Heather Desaire Methods of producing and purifying proteins
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
RU2682451C2 (ru) 2012-04-27 2019-03-19 Дайичи Санкио Компани, Лимитед Антитела к robo4
JP6445446B2 (ja) * 2012-11-08 2018-12-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨転移の治療のための方法及び医薬組成物
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
AU2018321825A1 (en) * 2017-08-19 2020-03-05 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (en) 1994-05-12 1996-12-18 Ono Pharmaceutical Co A polypeptide produced in an endothelial cell line and DNA encoding it.
US20040002591A1 (en) 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
EP1003763A4 (en) 1997-07-30 2003-02-19 Human Genome Sciences Inc 83 HUMAN SECRETED PROTEINS
JP2001514024A (ja) * 1997-09-05 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
DK1490386T3 (da) * 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
WO1999053051A2 (en) 1998-04-09 1999-10-21 Genset 5' ests and encoded human proteins
EP1263948A2 (en) 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
EP1210370A4 (en) * 1999-08-12 2004-06-09 Human Genome Sciences Inc TUMOR NECROSIS FACTOR TR16 HUMAN RECEPTOR
WO2001023523A2 (en) 1999-09-30 2001-04-05 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
JP2004524821A (ja) * 2000-11-06 2004-08-19 キャンサー・リサーチ・テクノロジー・リミテッド 疾患のイメージング、診断、及び治療
SI1572169T1 (sl) * 2002-03-08 2013-12-31 Shanghai Institutes For Biological Sciences, Cas Odkrivanje in modulacija slit in robo posredovane angiogeneze ter njuni načini uporabe
SI1565491T1 (sl) 2002-11-20 2010-08-31 Cancer Rec Tech Ltd Protitelesa, ki se veĹľejo na humani "magic roundabout (MR)", polipeptidi in njihove uporabe za inhibiranje angiogeneze

Also Published As

Publication number Publication date
JP2004524821A (ja) 2004-08-19
CY1107609T1 (el) 2013-03-13
US7498034B2 (en) 2009-03-03
CA2427310C (en) 2013-12-17
PT1790728E (pt) 2010-11-12
DE60143065D1 (de) 2010-10-21
US20080219924A1 (en) 2008-09-11
AU2378402A (en) 2002-05-15
EP1790728A3 (en) 2007-06-13
EP1334194B1 (en) 2007-04-18
CA2427310A1 (en) 2002-05-10
ATE360068T1 (de) 2007-05-15
PT1334194E (pt) 2007-07-17
US20070025913A1 (en) 2007-02-01
JP2010248210A (ja) 2010-11-04
AU2002223784B2 (en) 2007-01-18
WO2002036771A2 (en) 2002-05-10
DK1790728T3 (da) 2010-12-06
ATE480622T1 (de) 2010-09-15
ES2296829T3 (es) 2008-05-01
AU2007201584A1 (en) 2007-05-03
US20090191572A1 (en) 2009-07-30
EP1334194A2 (en) 2003-08-13
EP1790728A2 (en) 2007-05-30
US7740830B2 (en) 2010-06-22
US7582440B2 (en) 2009-09-01
US8216584B2 (en) 2012-07-10
DE60127986T2 (de) 2008-01-17
WO2002036771A3 (en) 2002-09-06
DE60127986D1 (de) 2007-05-31
JP5603145B2 (ja) 2014-10-08
CY1110967T1 (el) 2015-06-11
US20080145359A1 (en) 2008-06-19
US20080274045A9 (en) 2008-11-06
EP1790728B1 (en) 2010-09-08
US20040071711A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
DK1334194T3 (da) Afbildning, diagnosticering og behandling af sygdom
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1196444T3 (da) Exendin-4-konjugater og deres medicinske anvendelighed
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
BRPI0307673A2 (pt) métodos de tratar doença vascular.
ATE305932T1 (de) Rapanycin29-enole
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
DK1163904T3 (da) Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
DK0981343T3 (da) Probucolmonoestere til behandling af kardiovaskulær og inflammatorisk sygdom
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DK1782825T3 (da) Behandling af glycogenlagringssygdom type II
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE506959T1 (de) Verwendung von il-18 inhibitoren
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
NO20053903D0 (no) Nukleotidlipidesterderivater.
NO20060420L (no) 2-aminobenzoylderivater
DK1328289T3 (da) Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36
DK1253935T3 (da) Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
DE10045123B8 (de) Das C. albicans TEC1 GEN(CaTEC1) und das kodierte Tec1p Protein
ITTO20000109V0 (it) Protesi totale del ginocchio.